The European Medicines Agency (EMA) has extended the use of Mounjaro (Tirzepatide) for the treatment of type 2 diabetes in adolescents and children who are at the age of 10 or above.
The current treatment options available for children with type 2 diabetes were only limited with the use of Metformin and/or Insulin.
Tirzepatide, being sold under the brand name "Mounjaro" in the EU is already approved to treat adults with type 2 diabetes that is not satisfactorily controlled, which is also approved for weight loss in adults.
The committee recommended expanding the use of Mounjaro to patients aged 10 years and older with inadequately controlled type 2 diabetes, either as a monotherapy when metformin is not suitable due to intolerance or contraindications, or as an additional treatment combined with other diabetes medications.
Reference:
https://www.ema.europa.eu/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-8-11-december-2025